PTC
MYGN icon

Private Trust Company’s Myriad Genetics MYGN Stock Holding History

Private Trust Company’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-168
Closed -$6K – 860
2014
Q3 		$6K Sell
168
-300
-64% -$11.2K ﹤0.01% 1251
2014
Q2 		$18K Buy
468
+106
+29% +$3.94K 0.01% 863
2014
Q1 		$12K Sell
362
-63
-15% -$1.95K ﹤0.01% 908
2013
Q4 		$9K Buy
425
+300
+240% +$7.59K ﹤0.01% 992
2013
Q3 		$3K Hold
125
– – ﹤0.01% 1290
2013
Q2 		$3K Buy
+125
New +$3.62K ﹤0.01% 1226

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Private Trust Company's MYGN Position: Q4 2014 in Review

Private Trust Company sold out of Myriad Genetics (MYGN) in Q4 2014, closing a stake of 168 shares — an estimated $6K sold.

Private Trust Company first reported a position in MYGN in Q2 2013 and held it in 6 quarters. The position peaked at $18K in Q2 2014. 272 funds tracked by Wall St. Rank hold MYGN as of Q4 2014.

  • Private Trust Company reported no remaining Myriad Genetics position as of Q4 2014 after selling out during the quarter.
  • Private Trust Company sold 168 Myriad Genetics shares in Q4 2014, an estimated $6K.
  • Private Trust Company first reported a position in Myriad Genetics in Q2 2013 and held it in 6 quarters.
  • Private Trust Company's Myriad Genetics position peaked at $18K in Q2 2014.
  • 272 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2014.

Based on Private Trust Company's 13F filing for Q4 2014, filed 28 Jan 2015.